CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Lipid modification - primary and secondary CVD prevention - Management
What tests are recommended before starting lipid modification therapy?
- Perform the following tests (if not already done as part of the cardiovascular risk assessment):
- Two lipid measurements (with one measurement based on a fasting sample).
- A liver function test.
- Fasting blood glucose.
- Renal function.
- Creatine kinase, if the person is at high risk of experiencing muscle toxicity.
- Serum thyroid stimulating hormone (if dyslipidaemia is present).
In depth
© NHS Institute for Innovation and Improvement